Buy Lomflox pills 400 mg, 5 pcs
  • Buy Lomflox pills 400 mg, 5 pcs

Lomflox® [Lomefloxacin]

Ipka
730 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$28.45
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Antimicrobial broad-spectrum drug from the group of fluoroquinolones (difluoroquinolone with a piperazine group in the quinolone ring). Bactericidal effect. Inhibits the activity of a DNA gyrase enzyme involved in the transcription and replication of bacterial DNA. Highly active against gram-negative aerobic microorganisms:

Tsitrobakterov and Enterobakterov (including E. aerogenes and Enterobacter cloacae), bacteria - Escherichia coli, Salmonella spp, Shigella spp, Citrobacter diversus, Haemofilus influenzae, Klebsiella pneumoniae, Proteus vulgaris, Morganella morganiiii, Legionella pem cocci - Neisseria gonorrhoeae, Neisseria meningitidis, Moraxella catarrhalis.

Moderately lax hydrophila, Hafnia alvei, Mycobacterium tuberculosis, Chlamidia trachomatis, Bordetella pertussis, as well as some gram-positive aerobic microorganisms: Staphylococcus aureus, Staphylococcus epidermidis (lomefloxacin is much more effective than norfloxacin or glusexidics or epidermidis (much less effective than norfloxacin or foraxidus),

Resistant to the drug Streptococcus spp, Pseudomonas cepacia, Ureaplasma urealiticum and anaerobic bacteria. Cholera vibrio and parahemolytic vibrio are susceptible to lomefloxacin. Ureaplazma urealyticum, Mycoplasma pneumonae and Mycoplasma hominis are also sensitive to the drug.

It has a pronounced anti-tuberculosis activity. Most microorganisms act in low concentrations.

Resistance develops rarely, mainly to staphylococcus, Pseudomonas pneumonia.

Indications

Infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

  • uncomplicated and complicated urinary tract infections (cystitis, pyelonephritis, prostatitis);
  • acute and chronic gonorrhea;
  • acute and recurrent chlamydia, chlamydial conjunctivitis;
  • lower respiratory tract infections, including exacerbation of chronic bronchitis, pneumonia;
  • infections of bones and joints, including chronic ostiomyelitis;
  • acute and chronic purulent infections of soft tissues;
  • infectious enterocolitis and cholecystitis;
  • infected wounds;
  • obstetric and gynecological infections;
  • prophylaxis with transurethral intervention;
  • cholera (severe course);
  • tuberculosis (as part of combination therapy with major anti-tuberculosis drugs, as well as with resistance to anti-tuberculosis drugs).

Composition

1 coated tablet contains 400 mg of lomefloxacin hydrochloride.

No customer reviews for the moment.

Write your review

Write your review

Lomflox® [Lomefloxacin]

Dosage and Administration

In urinary tract infections, it is usually prescribed 400 mg 1 time per day for no more than 10 days (uncomplicated forms) or 10-14 days (complicated forms).

For acute gonorrhea, 600 mg is administered once, for chronic gonorrhea, 600 mg once a day for 5 days.

When urogenital chlamydia, including mixed bacterial chlamydial infection is used in a dose of 400-600 mg once a day for 28 days.

For acute and chronic purulent infections of soft tissues, infected wounds are prescribed 400 mg 1 time per day for 5-14 days.

When ostiomyelitis is used in a dose of 400-800 mg per day. The course of treatment is up to 14 days.

For prophylaxis before transurethral surgery, it can be administered as a single dose of 400 mg 2-6 hours before the procedure.

In severe cholera, 400 mg is prescribed 1 time per day for 5 days.

For tuberculosis, a dose of 400 mg is applied 2 times a day for 14-28 days, if necessary, for a longer time.

For infections of the lower respiratory tract, acute bronchitis, bronchopneumonia prescribed at a dose of 400 mg per day for 10 days.

Elderly patients in most cases, you can assign the usual dose, if they have a creatinine clearance of at least 40 ml / min.

In patients with renal and hepatic insufficiency with creatinine clearance less than 40 ml / min, the doses should be changed in accordance with the degree of renal failure. For the initial dose of 400 mg should follow the dose of 200 mg 1 time per day during the course of treatment. There is no need to reduce the dose for patients with cirrhosis of the liver, if the renal function is adequate. Take the drug, regardless of the meal.

Adverse reactions

Rarely: nausea, diarrhea, epigastric pain, headache, sleep disturbances, mood swings, agitation, tremor, depression.

Contraindications

With excessive exposure to ultraviolet rays, a moderate photosensitization effect may be observed. In this case, treatment should be discontinued. May cause arthropathy in a growing body. Allergic reactions in the form of skin rash and other manifestations are possible.

  • pregnancy and lactation;
  • hypersensitivity to lomefloxacin and other quinolones;
  • children and teenagers under the age of 18 years.

Drug interactions

Polysaccharides with anti-pepsin action or antacids containing magnesium or aluminum should not be used within 4 hours before and 2 hours after taking Lomefloxacin, since this reduces its bioavailability. Mineral supplements or vitamins containing iron or minerals should not be taken within 2 hours after ingestion. There is evidence that H2-antagonists (cimetidine, ranitidine) can disrupt quinolone elimination, which leads to an increase in half-life and PEP.

Unlike other quinolones, it does not inhibit theophylline metabolism, so recalculation of theophylline dose is not needed.

Quinolones may exacerbate the effect of oral anticoagulants of warfarin or its derivatives, with their concomitant use. Prothrombin or other coagulation parameters must be checked and monitored.

There is no cross-resistance with penicillins, cephalosporins, aminoglycosides, co-trimoxazole, metronidazole.

Lomflox use in combination therapy with isoniazid, pyrazinamide, streptomycin, ethambutol.

Special instructions

With caution prescribed to patients with severe cerebral atherosclerosis, suffering from epilepsy and other diseases of the central nervous system.

If such symptoms as convulsions, agitation, photophobia, confusion, hallucinations appear on the background of treatment, the drug should be canceled.

During treatment it is recommended to avoid prolonged exposure to sunlight or ultraviolet light. When used during lactation, it is necessary to resolve the issue of discontinuing breastfeeding.

It may cause dizziness and impaired attention, so you should not engage in activities requiring coordination (work on complex equipment, drive a car).

At the level of other quinolones, it can interfere with caffeine metabolism (tea / coffee), reducing clearance, extending the half-life and increasing the symptoms of caffeine overdose.

During the course of treatment it is necessary to increase the amount of fluid consumed.

  • Brand name: Lomflox
  • Active ingredient: Lomefloxacin
  • Dosage form: Pills.
  • Manufacturer: Ipka
  • Country of Origin: India

Studies and clinical trials of Lomefloxacin (Click to expand)

  1. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat
  2. Pharmacokinetics and safety of single oral doses of lomefloxacin
  3. Development and validation of a fast isocratic liquid chromatography method for the simultaneous determination of norfloxacin, lomefloxacin and ciprofloxacin in human plasma
  4. Modeling the Photochemistry of the Reference Phototoxic Drug Lomefloxacin by Steady-State and Time-Resolved Experiments, and DFT and Post-HF Calculations
  5. ChemInform Abstract: The Photochemistry of Lomefloxacin. An Aromatic Carbene as the Key Intermediate in Photodecomposition.
  6. Spectroscopic Study on Interaction of Lomefloxacin with Human Serum Albumin in the Presence of Copper Ion
  7. Photochemistry of the Phototoxic Drug Lomefloxacin: Paths Observed in the Presence of Amines or NaOH and from the Methyl Ester
  8. Electrochemical Studies of Oxidation of Lomefloxacin and Interaction with Calf Thymus DNA at Nano-SnO2/DHP Modified Electrode
  9. Use of centromeric and telomeric DNA probes in in situ hybridization for differentiation of micronuclei induced by lomefloxacin
  10. Serum protein binding of lomefloxacin, a new antimicrobial agent, and its related quinolones
  11. Determination of ofloxacin and lomefloxacin in chicken muscle using molecularly imprinted solid-phase extraction coupled with liquid chromatography
  12. Ion-pairing and reversed phase liquid chromatography for the determination of three different quinolones: Enrofloxacin, lomefloxacin and ofloxacin
  13. Separation of seven fluoroquinolones by microemulsion electrokinetic chromatography and application to ciprofloxacin, lomefloxacin determination in urine
  14. Voltammetric study of the interaction of lomefloxacin (LMF)–Mg(II) complex with DNA and its analytical application
  15. Determination of lomefloxacin in human plasma by solid-phase extraction and high-performance liquid chromatography with UV detection
  16. A 19F NMR study of lomefloxacin in human erythrocytes and its interaction with hemoglobin
  17. Stereospecific high-performance liquid chromatographic assay of lomefloxacin in human plasma
  18. Automated analytical systems for drug development studies part IV. A microdialysis system to study the partitioning of lomefloxacin across an erythrocyte membrane in vitro
  19. A novel spectrofluorimetric method for determination of lomefloxacin based on supramolecular inclusion complex between it and p-sulfonated calyx[4]arene
  20. EPR examination of free radical properties of DOPA–melanin complexes with ciprofloxacin, lomefloxacin, norfloxacin and sparfloxacin
  21. Highly sensitive spectrofluorimetric determination of lomefloxacin in spiked human plasma, urine and pharmaceutical preparations
  22. Enantioseparation of lomefloxacin hydrochloride by high-speed counter-current chromatography using sulfated-β-cyclodextrin as a chiral selector
  23. Characterization of the interaction between human lactoferrin and lomefloxacin at physiological condition: Multi-spectroscopic and modeling description
  24. Spectroscopic and nano-molecular modeling investigation on the binary and ternary bindings of colchicine and lomefloxacin to Human serum albumin with the viewpoint of multi-drug therapy

8 other products in the same category:

arrow_upward